

Hatch Medical to Broker Novel Hydra™ Bifurcated Coronary Balloon Catheter

Atlanta, Georgia – Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm, announced today that it has recently entered into an agreement with physician inventor, Khalid Al-Saadon, M.D. and his company, Medix Innovators, Inc. to broker the sale or license of its patented, bifurcated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter system.

Coronary artery disease costs in the United States are expected to rise from \$273 billion in 2010 to \$818 billion in 2030. Percutaneous Coronary Intervention (PCI) is the least invasive and most cost-effective method for treating coronary artery disease, and bifurcated lesions account for 15-20 % of PCI cases. As a result, the PCI market for bifurcation lesions ranges from \$ 450-600 million in the U.S. alone.

Medix Innovator’s unique balloon catheter design and construction facilitates the efficient and cost effective delivery of stents, stent-grafts, pharmacological agents or angioplasty to bifurcated vessels. As an example, many stents delivered to bifurcated lesions utilize the “kissing balloon” technique. This procedure requires the use of two PTCA balloon catheters that are independently advanced to a vessel’s bifurcation and inflated. This technique has inherent risks, as the possibility of over dilation of the primary vessel is a concern, along with the increased costs of utilizing two catheters. Medix’s Hydra™ solves both concerns by providing a system that efficiently delivers variable-sized balloons to accommodate both main and branch vessels – [watch the demonstration video](#).

“We are very excited to be working with the Medix team and representing such an innovative technology that will not only help resolve the numerous challenges associated with the treatment of bifurcated lesions, but also reduce procedural costs.”, commented Paul Gianneschi, Managing Principal at Hatch Medical, L.L.C.

Dr. Khalid Al-Saadon, internal medicine specialist practicing cardiology and President of Medix Innovators, Inc., commented, “We are very excited to offer an efficient, cost-effective solution for the treatment of bifurcated disease and are grateful to have the expertise of Hatch Medical. We look

forward to securing a partner that recognizes the remarkable potential of this technology.”

Medix Innovators, LLC and its associated technologies are available for acquisition or license through an exclusive agreement with Hatch Medical. For additional information on this, or other Hatch Medical, L.L.C. products and services, e-mail the company at info@hatchmedical.com. This release and additional news about Hatch Medical can be obtained by visiting the company’s web site at:

<http://www.hatchmedical.com>.

Contact Paul Gianneschi, Managing Principal, 770-476-9940 or Steve Hvozda, Principal 949-388-9335